Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 20/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 20/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | NQO2 | P16083 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612779 | 0.90 | MTNR1B (0.69) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL14327014 | 0.86 | MTNR1B (0.64) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1643499 | 0.86 | MTNR1B (0.66) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL14493649 | 0.81 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL10053045 | 0.80 | MTNR1B (0.56) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL2459178 | 0.77 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL2459176 | 0.77 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL2462986 | 0.77 | MTNR1A (0.66) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL2462981 | 0.77 | MTNR1A (0.66) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1566407 | 0.77 | MTNR1A (0.66) | MTNR1AMTNR1BABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036521-A1 | Process for Production of Optically Active Amine Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036521-A1 | Process for Production of Optically Active Amine Derivatives | INMT, TYR, PNMT | MTNR1A 3077/4885MTNR1B 2236/4885ABCB11 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.